How are leading Pharma researchers using HTS to identify kinase inhibitors? Protein kinases play crucial roles in biological processes and aberrant kinase activity in human disease including cancer and autoimmune diseases.
Listen to an in-depth discussion with leading Pharma researchers who are targeting kinases for the development of new drugs. • Protein kinases account for 25% to 30% of all targets screened in the pharmaceutical industry today. Which targets offer the most potential? • Fast, reliable, high-throughput screening methods are necessary to determine which potential kinase inhibitors are worthy of further clinical development and which are not. Which processes work best? • Screening platforms based on a variety of different technologies are currently available, but all of them have inherent technical challenges that can affect results; this Webcast discusses some of the challenges. View on Demand Now |
Moderator:
James Netterwald, Ph.D., MT (ASCP)
Senior Editor
Drug Discovery & Development Panelists:
Kirk McMillan, Ph.D.
Vice President, Lead Discovery
Exelixis, Inc.
Kim Arndt, Ph.D.
Senior Director, Oncology
Wyeth Research Pirthipal Singh
Associate Principal Scientist; DECS-LG
AstraZeneca Click here to view Q&A. |